Neurofibromatosis

Jump to navigation Jump to search
Neurofibromatosis
Back of an elderly woman with Neurofibromatosis.
ICD-10 Q85.0
ICD-9 237.7
ICD-O: 9540/0
eMedicine derm/287 
MeSH D017253

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

WikiDoc Resources for Neurofibromatosis

Articles

Most recent articles on Neurofibromatosis

Most cited articles on Neurofibromatosis

Review articles on Neurofibromatosis

Articles on Neurofibromatosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Neurofibromatosis

Images of Neurofibromatosis

Photos of Neurofibromatosis

Podcasts & MP3s on Neurofibromatosis

Videos on Neurofibromatosis

Evidence Based Medicine

Cochrane Collaboration on Neurofibromatosis

Bandolier on Neurofibromatosis

TRIP on Neurofibromatosis

Clinical Trials

Ongoing Trials on Neurofibromatosis at Clinical Trials.gov

Trial results on Neurofibromatosis

Clinical Trials on Neurofibromatosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Neurofibromatosis

NICE Guidance on Neurofibromatosis

NHS PRODIGY Guidance

FDA on Neurofibromatosis

CDC on Neurofibromatosis

Books

Books on Neurofibromatosis

News

Neurofibromatosis in the news

Be alerted to news on Neurofibromatosis

News trends on Neurofibromatosis

Commentary

Blogs on Neurofibromatosis

Definitions

Definitions of Neurofibromatosis

Patient Resources / Community

Patient resources on Neurofibromatosis

Discussion groups on Neurofibromatosis

Patient Handouts on Neurofibromatosis

Directions to Hospitals Treating Neurofibromatosis

Risk calculators and risk factors for Neurofibromatosis

Healthcare Provider Resources

Symptoms of Neurofibromatosis

Causes & Risk Factors for Neurofibromatosis

Diagnostic studies for Neurofibromatosis

Treatment of Neurofibromatosis

Continuing Medical Education (CME)

CME Programs on Neurofibromatosis

International

Neurofibromatosis en Espanol

Neurofibromatosis en Francais

Business

Neurofibromatosis in the Marketplace

Patents on Neurofibromatosis

Experimental / Informatics

List of terms related to Neurofibromatosis

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Neurofibromatosis is a genetically-inherited disease in which nerve tissue grows tumors (e.g. neurofibromas) that may be harmless or may cause serious damage by compressing nerves and other tissues. The disorder affects all neural crest cells (Schwann cells, melanocytes, endoneurial fibroblasts). Cellular elements from these cell types proliferate excessively throughout the body forming tumors and the melanocytes function abnormally resulting in disordered skin pigmentation.The tumors may cause bumps under the skin, colored spots, skeletal problems, pressure on spinal nerve roots, and other neurological problems. [1]

Neurofibromatosis is autosomal dominant, which means that it affects males and females equally and is dominant (only one copy of the affected gene is needed to get the disorder). Therefore, if only one parent has neurofibromatosis, his or her children have a 50% chance of developing the condition as well. Disease severity in affected individuals, however, can vary (this is called variable expressivity). Moreover, in around half of cases there is no other affected family member because a new mutation has occurred.

Types

Diagnostic Criteria

Neurofibromatosis type 1

Neurofibromatosis type 1 - mutation of neurofibromin chromosome 17q11.2. The diagnosis of NF1 is made if any two of the following seven criteria are met:

  • Two or more neurofibromas on the skin or under the skin or one plexiform neurofibroma (a large cluster of tumors involving multiple nerves); Neurofibromas are the subcutaneous lumps that are characteristic of the disease and increase in number with age.
  • Freckling of the groin or the axilla (arm pit).
  • Café au lait spots (pigmented birthmarks). Six or more measuring 5 mm in greatest diameter in prepubertal individuals and over 15 mm in greatest diameter in postpubertal individuals
  • Skeletal abnormalities, such as sphenoid dysplasia or thinning of the cortex of the long bones of the body (i.e. bones of the leg, potentially resulting in bowing of the legs)
  • Lisch nodules (hamartomas of iris), freckling in the iris.
  • Tumors on the optic nerve, also known as an optic glioma
  • A first-degree relative with a diagnosis of NF1

Neurofibromatosis type 2

Neurofibromatosis type 2 - mutation of merlin chromosome 22q12

Schwannomatosis

Schwannomatosis - gene involved has yet to be identified

  1. Multiple Schwannomas occur.
  2. The Schwannomas develop on cranial, spinal and peripheral nerves.
  3. Chronic pain, and sometimes numbness, tingling and weakness.
  4. About 1/3 of patients have segmental Schwannomatosis, which means that the Schwannomas are limited to a single part of the body, such as an arm, a leg or the spine.
  5. Unlike the other forms of NF, the Schwannomas do not develop on vestibular nerves, and as a result, no loss of hearing is associated with Schwannomatosis.
  6. Patients with Schwannomatosis do not have learning disabilities related to the disease.

One must keep in mind, however, that neurofibromatosis can't occur in or affect any of the organ systems, whether that entails simply compressing them (from tumor growth) or in fact altering the organs in some fundamental way. This disparity in the disease is one of many factors that makes it difficult to diagnose, and eventually find a prognosis for.

Genetics and Hereditability

NF-1 and NF-2 may be inherited in an autosomal dominant fashion, as well as through random mutation.

Neurofibromatosis type 1 is due to mutation on chromosome 17q11.2 , the gene product being Neurofibromin ( a GTPase activating enzyme).[2]

Neurofibromatosis type 2 is due to mutation on chromosome 22q , the gene product is Merlin, a cytoskeletal protein.

Both NF1 and NF2 are autosomal dominant disorders, meaning that only one copy of the mutated gene need be inherited to pass the disorder. A child of a parent with NF1 or NF2 and an unaffected parent will have a 50% chance of inheriting the disorder.

Complicating the question of heritability is the distinction between genotype and phenotype, that is, between the genetics and the actual manifestation of the disorder.

In the case of NF1, no clear links between genotype and phenotype have been found, and the severity and specific nature of the symptoms may vary widely among family members with the disorder.[3] In the case of NF2, however, manifestations are similar among family members; a strong genotype-phenotype correlation is believed to exist (ibid).

Both NF1 and NF2 can also appear to be spontaneous mutation, with no family history. These cases account for about one half of neurofibromatosis cases (ibid).

Similar to polydactyly, although NF is a dominant mutation, it is not prevalent in society. Neurofibromatosis-1 is found in approximately 1 in 2,500-3,000 live births (carrier incidence 0.0004, gene frequency 0.0002). NF-2 is less common, having one case in 50,000-120,000 live births.[4]

Mechanism

Neurofibromatosis affects humans on a genetic level, meaning that it either destroys, or renders defective a specific gene. NF-1

  • The gene that NF-1 affects is large, on band 17q11.2. It encodes for a protein called neurofibromin, otherwise known as "the tumor suppressor" protein. Neurofibromatosis alters or weakens this protein, rapid, radical growth of cells is allowed all over the body, especially around the nervous system. This leads to the normal symptoms for neurofibromatosis - clumpings of these tumors, called neurofibromas and schwannomas.
  • Less is known about the NF-2 linked gene. However, it is on band 22q1 and also codes for a protein, most likely one similar to NF-1's.

Effects

People with Neurofibromatosis can be affected in many different ways.

  • There is a high incidence of learning disabilities in people with NF. It is believed that at least 50% of people with NF have learning disabilities of some type.
  • increased chances of development of petit mal epilepsy (a Partial absence seizure disorder)
  • The tumors that occur can grow anywhere a nerve is present. This means that:
    • They can grow in places that are very visible to people that a patient may encounter on the street.
    • The tumors can also grow in places that can cause other medical issues that may require them to be removed for the patient's safety.
  • Affected individuals may need multiple surgeries, depending on where the tumors are located.

Treatment

Because there is no cure for the disease itself, the only therapy for people with neurofibromatosis is a program of treatment by a team of specialists to manage symptoms or complications. Surgery may be needed when the tumors compress organs or other structures. Less than 10% people with neurofibromatosis develop cancerous growths; in these cases, chemotherapy may be successful.[5]

History

Neurofibromatosis was discovered in 1882 by the German pathologist Friedrich Daniel von Recklinghausen. He wrote on it and published it in Hämochromatose, Tageblatt der Naturforschenden Versammlung.[6]

Joseph Merrick, the Elephant Man, was once considered to have been affected with either elephantiasis or neurofibromatosis type I. However, it is now generally believed that Merrick suffered from the very rare Proteus syndrome. This however has given rise to the common misconception that Neurofibromatosis and "Elephant Man Disease" are one and the same.

Related disorders

Neurofibromatosis is considered a member of the neurocutaneous syndromes (phakomatoses). In addition to the types of neurofibromatosis, the phakomatoses also include tuberous sclerosis, Sturge-Weber syndrome and von Hippel-Lindau disease. This grouping is an artifact of an earlier time in medicine, before the distinct genetic basis of each of these diseases was understood.

Case Examples

Case #1

Clinical Summary

This 45-year-old divorced white male came to the emergency room with severe hepatic cirrhosis and aspiration pneumonia. Shortly after admission he developed cardiac arrhythmias and died. Significant past history included alcohol abuse, cirrhosis, and neurofibromatosis. He had no family history of neurofibromatosis, but his condition was diagnosed at age 17 when he developed neurofibromas along the lateral chest wall. There was no history of continued follow-up after this initial diagnosis.

Autopsy Findings

The patient was covered with variably sized subcutaneous nodules ranging from 0.5 to 2.5 cm in diameter. Other significant findings included micronodular hepatic cirrhosis (liver weight: 1760 grams), ascites (500 ml), and splenomegaly (weight: 260 grams).

Histopathological Findings

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

This photograph, taken at autopsy, demonstrates the distribution of neurofibromas on the skin of this patient.


This is another view taken at autopsy demonstrating the neurofibromas. Some lesions can be seen as subcutaneous swellings (arrow) and others form pedunculated masses. Most are hyperpigmented.


This is a closer view of neurofibromas on the skin.


This is a low-power photomicrograph of a subcutaneous neurofibroma (1). Note the increased pigmentation in the skin (2).


This is a higher-power photomicrograph of the neurofibroma (1) with the overlying skin (2).





See also

References

  1. http://www.merck.com/mmhe/sec06/ch088/ch088d.html Merck Manual Home Edition, "Neurofibromatosis"
  2. Fauci, et al Harrison's Principle of Internal Medicine 16th Ed. p 2453
  3. Korf, Bruce E. and Allan E. Rubenstein. 2005. Neurofibromatosis: A Handbook for Patients, Families, and Health Care Professionals.
  4. Jennifer R. Kam, Jan. 2007
  5. Neurofibromatosis. JAMA patient page, Vol. 300 No. 3, July 16, 2008.
  6. Template:WhoNamedIt

External links

Template:SIB Template:Nervous tissue tumors

de:Neurofibromatose it:Neurofibromatosi lt:Neurofibromatozė hu:Neurofibromatózis nl:Neurofibromatose no:Nevrofibromatose sv:Neurofibromatos

Template:WH Template:WS